Nu­va­tion Bio scores first FDA ap­proval for new lung can­cer drug

Nu­va­tion Bio on Wednes­day won FDA ap­proval with its first com­mer­cial­ized drug, Ib­trozi, for ad­vanced ROS1-pos­i­tive non-small cell lung can­cer (NSCLC).

The ap­proval of Ib­trozi …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER